Target Discovery and Validation Reviews and Protocols

More documents

Recommendations

Info

Heart Failure and Immunity 275 6. Woldbaek, P. R., Tonnessen, T., Henriksen, U. L., et al. (2003) Increased cardiac IL-18 mRNA, pro-IL-18 and plasma IL-18 after myocardial infarction in the mouse: a potential role in cardiac dysfunction. Cardiovasc. Res. 59, 122–131. 7. Bohm, J. (2000) Gelatinous transformation of the bone marrow: the spectrum of underlying diseases. Am. J. Surg. Pathol. 24, 56–65. 8. Ezekowitz, J. A., McAlister, F. A., and Armstrong, P. W. (2003) Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 107, 223–225. 9. Mozaffarian, D., Nye, R., and Levy, W. C. (2003) Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J. Am. Coll. Cardiol. 41, 1933–1939. 10. Kalra, P. R., Collier, T., Cowie, M. R., et al. (2003) Haemoglobin concentration and prognosis in new cases of heart failure. Lancet 362, 211–212. 11. Iversen, P. O., Woldbaek, P. R., Tonnessen, T., and Christensen, G. (2002) Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am. J. Physiol. 282, R166–R172. 12. Iversen, P. O., Woldbaek, P. R., and Christensen, G. (2005) Reduced immune responses to an aseptic inflammation in mice with congestive heart failure. Eur. J. Haematol. 75, 156–163. 13. Rehbinder, C., Baneux, P., Forbes, D., et al. (1996) FELASA recommendations for the health monitoring of mouse, rat, hamster, gerbil, guinea pig and rabbit experimental units. Lab. Anim. 30, 193–208. 14. Mahabir, E., Jacobsen, K., Brielmeier, M., Peters, D., Needham, J., and Schmidt, J. (2004) Mouse antibody production test: can we do without it? J. Virol. Methods 120, 239–245. 15. Finsen, A. V., Christensen, G., and Sjaastad, I. (2005) Echocardiographic parameters discriminating myocardial infarction with pulmonary congestion from myocardial infarction without congestion in the mouse. J. Appl. Physiol. 98, 680–689.
Page 1 and 2:
METHODS IN MOLECULAR BIOLOGY 360 T
Page 3 and 4:
M E T H O D S I N M O L E C U L A R
Page 5 and 6:
© 2007 Humana Press Inc. 999 River
Page 7 and 8:
vi Preface get. Approaches to targe
Page 9 and 10:
viii Contents 10 Transgenic Animal
Page 11 and 12:
x Contributors SAHOHIME MATSUMOTO
Page 13 and 14:
xii Contents of Volume 2 12 Validat
Page 15 and 16:
2 Sioud disease pathogenesis and pe
Page 17 and 18:
4 Sioud A more fruitful approach fo
Page 19 and 20:
6 Sioud both transient and permanen
Page 21 and 22:
8 Sioud serum biomarkers. This syne
Page 23 and 24:
10 Sioud Fig. 2. Schematic of targe
Page 25 and 26:
12 Sioud 13. Magin, T. M. (1998) Le
Page 28 and 29:
Harnessing the Human Genome 15 The
Page 30 and 31:
Harnessing the Human Genome 17 Fig.
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Harnessing the Human Genome 23 The
Page 38 and 39:
Page 40 and 41:
Harnessing the Human Genome 27 repr
Page 42 and 43:
Harnessing the Human Genome 29 14.
Page 44:
Harnessing the Human Genome 31 45.
Page 47 and 48:
34 Imoto et al. (4,5), and Bayesian
Page 49 and 50:
36 Imoto et al. 2. Materials Two ty
Page 51 and 52:
38 Imoto et al. Fig. 3. Graphical v
Page 53 and 54:
40 Imoto et al. Fig. 5. Result of t
Page 55 and 56:
42 Imoto et al. p(D |G) = ∫ p(D,
Page 57 and 58:
44 Imoto et al. β k (k = 1,…,q j
Page 59 and 60:
46 Imoto et al. Fig. 7. Partial res
Page 61 and 62:
48 Imoto et al. Fig. 8. Strategy to
Page 63 and 64:
50 Imoto et al. Fig. 9. (continued)
Page 65 and 66:
52 Imoto et al. Table 3 List of Roo
Page 67 and 68:
54 Imoto et al. 5. De Hoon, M. J. L
Page 69 and 70:
56 Imoto et al. 39. Kamimura, T., S
Page 71 and 72:
58 Beaty et al. cytotoxic drugs and
Page 73 and 74:
60 Beaty et al. Fig. 1. Principles
Page 75 and 76:
62 Beaty et al. oligonucleotide mic
Page 77 and 78:
64 Beaty et al. 3. The 12% polyacry
Page 79 and 80:
66 Beaty et al. 2.3.3. Protein Stai
Page 81 and 82:
68 Beaty et al. 3.1.3. Labeling of
Page 83 and 84:
70 Beaty et al. 1 µL of the anneal
Page 85 and 86:
72 Beaty et al. 4. Phenol:cholorfor
Page 87 and 88:
74 Beaty et al. 19. Wash twice with
Page 89 and 90:
76 Beaty et al. The Following Volum
Page 91 and 92:
78 Beaty et al. using a protein ass
Page 93 and 94:
80 Beaty et al. 6. Shake the gel fo
Page 95 and 96:
82 Beaty et al. Fig. 2. Preparation
Page 97 and 98:
84 Beaty et al. search in. A widely
Page 99 and 100:
86 Beaty et al. 3. Kern, S. E., Hru
Page 101 and 102:
88 Beaty et al. 34. Peters, D. G.,
Page 104 and 105:
5 Molecular Classification of Breas
Page 106 and 107:
Molecular Profiling of Breast Cance
Page 108 and 109:
Page 110 and 111:
Fig. 2. (Continued) the right ident
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
6 Discovery of Differentially Expre
Page 130 and 131:
Gene Target Discovery 117 In the fi
Page 132 and 133:
Gene Target Discovery 119 sequences
Page 134 and 135:
Gene Target Discovery 121 There is
Page 136 and 137:
Gene Target Discovery 123 digestion
Page 138 and 139:
Gene Target Discovery 125 Fig. 1. P
Page 140 and 141:
Gene Target Discovery 127 5. Sargen
Page 142:
Gene Target Discovery 129 41. Berry
Page 145 and 146:
132 Matsumoto, Miyagishi, and Taira
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
144 Fig. 1. The ribozyme-expression
Page 159 and 160:
146 Sano and Taira 5. 10X L (low-sa
Page 161 and 162:
148 Sano and Taira ribozymes may cl
Page 163 and 164:
150 Fig. 3. A system for the identi
Page 165 and 166:
152 Sano and Taira 4. Notes 1. We r
Page 168 and 169:
9 Production of siRNA- and cDNA-Tra
Page 170 and 171:
Transfected Cell Arrays 157 Fig. 1.
Page 172 and 173:
Transfected Cell Arrays 159 2. The
Page 174:
Transfected Cell Arrays 161 5. Simp
Page 177 and 178:
164 Houdebine Fig. 1. Different met
Page 179 and 180:
166 Houdebine concentrations become
Page 181 and 182:
168 Houdebine Fig. 2. Major methods
Page 183 and 184:
170 Houdebine integrate into the me
Page 185 and 186:
172 Houdebine 2.2.3. Knock-In Into
Page 187 and 188:
174 Houdebine as insulators. The co
Page 189 and 190:
176 Houdebine Fig. 5. Different met
Page 191 and 192:
178 Houdebine systems. Moreover, st
Page 193 and 194:
180 Houdebine contribute to generat
Page 195 and 196:
182 Houdebine Fig.7. Example of a v
Page 197 and 198:
184 Houdebine more extensively. Tra
Page 199 and 200:
186 Houdebine and stroma. Several o
Page 201 and 202:
188 Houdebine explained at the mole
Page 203 and 204:
190 Houdebine of the intestinal epi
Page 205 and 206:
192 Houdebine interference of the g
Page 207 and 208:
194 Houdebine 17. Whitelaw, C. B. A
Page 209 and 210:
196 Houdebine 51. Bell, A. C., West
Page 211 and 212:
198 Houdebine 86. Carmichael, G. G.
Page 213 and 214:
200 Houdebine 121. Pailhoux, E., Vi
Page 215 and 216:
202 Houdebine 156. Auerbach, A. B.,
Page 217 and 218:
204 Vijayaraj, Söhl, and Magin 1.
Page 219 and 220:
206 Vijayaraj, Söhl, and Magin Fig
Page 221 and 222:
208 Vijayaraj, Söhl, and Magin fil
Page 223 and 224:
210 Table 1 Orthologous Human and M
Page 225 and 226:
212 Table 2 Orthologous Human and M
Page 227 and 228:
214 Vijayaraj, Söhl, and Magin ulc
Page 229 and 230:
216 Vijayaraj, Söhl, and Magin of
Page 231 and 232:
218 Vijayaraj, Söhl, and Magin sug
Page 233 and 234:
220 Vijayaraj, Söhl, and Magin abs
Page 235 and 236:
222 Vijayaraj, Söhl, and Magin 1.2
Page 237 and 238: 224 Vijayaraj, Söhl, and Magin Fig
Page 239 and 240: 226 Vijayaraj, Söhl, and Magin gen
Page 241 and 242: 228 Vijayaraj, Söhl, and Magin the
Page 243 and 244: 230 Vijayaraj, Söhl, and Magin f.
Page 245 and 246: 232 Vijayaraj, Söhl, and Magin 3.
Page 247 and 248: 234 Vijayaraj, Söhl, and Magin b.
Page 253 and 254: 240 Vijayaraj, Söhl, and Magin alt
Page 255 and 256: 242 Table 3 Time Schedule For Aggre
Page 263 and 264: 250 Vijayaraj, Söhl, and Magin 101
Page 266 and 267: 12 The HUVEC/Matrigel Assay An In V
Page 269 and 270: 256 Skovseth, Küchler, and Haralds
Page 283 and 284: 270 Iversen and Sørensen witnessed
Page 285 and 286: 272 Iversen and Sørensen Fig. 1. P
Page 287: 274 Iversen and Sørensen the core
Page 291 and 292: 278 Sioud gene products have been d
Page 293 and 294: 280 Sioud Fig. 1. Schematic of hema
Page 295 and 296: 282
Page 297 and 298: 284
Page 299 and 300: 286 Sioud selection), whereas thymo
Page 301 and 302: 288 Sioud Fig. 5. Affinity maturati
Page 303 and 304: 290 Sioud Fig. 6. A second signal i
Page 305 and 306: 292 Sioud Fig. 7. Bridging between
Page 307 and 308: 294 Sioud Fig. 8. Schematic of clas
Page 309 and 310: 296 Sioud Fig. 10. Critical molecul
Page 311 and 312: 298 Sioud In contrast to the expres
Page 313 and 314: 300 Sioud tumor infiltrating lympho
Page 315 and 316: 302 Sioud (see Chapter 15, Volume 1
Page 317 and 318: 304 Sioud display if the foreign pr
Page 319 and 320: 306 Sioud Fig. 13. Immunoscreening
Page 321 and 322: 308 Sioud molecular techniques have
Page 323 and 324: 310 Sioud Although much of the init
Page 325 and 326: 312 Sioud Because of their importan
Page 327 and 328: 314 Sioud 22. He, X., Janeway, C. A
Page 329 and 330: 316 Sioud 59. Sahin, U., Tureci, O.
Page 331 and 332: 318 Sioud 91. Golgher, D., Jones, E
Page 333 and 334: 320 Jäger Furthermore, this immune
Page 335 and 336: 322 Jäger Antigens that are tumor-
Page 337 and 338: 324 Jäger 2. Nakano, O., Sato, M.,
Page 339 and 340:
326 Jäger 31. Chen, Y. T., Gure, A
Page 341 and 342:
328 Le Naour dependent on CD8+ cyto
Page 343 and 344:
330 Le Naour Fig. 1. To illustrate
Page 345 and 346:
332 Le Naour heterogeneity of HCC,
Page 347 and 348:
334 Le Naour 15. Le Naour, F., Mise
Page 349 and 350:
336 Cekaite, Hovig, and Sioud Yeast
Page 351 and 352:
338 Cekaite, Hovig, and Sioud diffe
Page 353 and 354:
340
Page 355 and 356:
342 Cekaite, Hovig, and Sioud nonra
Page 357 and 358:
344 Cekaite, Hovig, and Sioud 3. Ue
Page 359 and 360:
346 Cekaite, Hovig, and Sioud 32. T
Page 361 and 362:
348 Cekaite, Hovig, and Sioud 65. L
Page 363 and 364:
350 Index Centroblast, 289 Centrocy
Page 365 and 366:
352 Index L Labeling mRNA, 62 Large
Page 367:
354 Index Tetraploid embryos, 239 g
show all

Target Discovery and Validation Reviews and Protocols

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?